6,600 Shares in Celsius Holdings, Inc. (NASDAQ:CELH) Purchased by Falcon Wealth Planning

Falcon Wealth Planning bought a new position in Celsius Holdings, Inc. (NASDAQ:CELH) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,600 shares of the company’s stock, valued at approximately $613,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. raised its position in shares of Celsius by 20.9% in the first quarter. Envestnet Asset Management Inc. now owns 5,908 shares of the company’s stock worth $326,000 after acquiring an additional 1,023 shares during the period. JPMorgan Chase & Co. raised its holdings in Celsius by 8.5% in the 1st quarter. JPMorgan Chase & Co. now owns 54,953 shares of the company’s stock worth $3,033,000 after purchasing an additional 4,285 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Celsius by 4.3% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,583 shares of the company’s stock worth $529,000 after purchasing an additional 398 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Celsius by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 394,530 shares of the company’s stock valued at $21,771,000 after purchasing an additional 7,411 shares during the period. Finally, MetLife Investment Management LLC raised its stake in shares of Celsius by 53.1% during the 1st quarter. MetLife Investment Management LLC now owns 28,662 shares of the company’s stock worth $1,582,000 after buying an additional 9,946 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Celsius

In related news, major shareholder Hoi Shuen Solina Holly Chau sold 350,976 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $142.46, for a total transaction of $50,000,040.96. Following the completion of the transaction, the insider now directly owns 7,980,323 shares in the company, valued at approximately $1,136,876,814.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Celsius news, major shareholder Hoi Shuen Solina Holly Chau sold 350,976 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $142.46, for a total value of $50,000,040.96. Following the completion of the transaction, the insider now owns 7,980,323 shares in the company, valued at $1,136,876,814.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Alexandre Ruberti sold 4,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $175.25, for a total value of $701,000.00. Following the sale, the director now directly owns 15,805 shares in the company, valued at approximately $2,769,826.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 873,608 shares of company stock worth $141,962,128. 2.70% of the stock is currently owned by company insiders.

Celsius Stock Performance

Shares of NASDAQ CELH traded down $0.08 during mid-day trading on Tuesday, reaching $199.35. 411,575 shares of the company’s stock were exchanged, compared to its average volume of 1,133,137. The company’s 50-day moving average is $165.00 and its 200-day moving average is $129.97. The firm has a market capitalization of $15.33 billion, a price-to-earnings ratio of -104.41 and a beta of 1.78. Celsius Holdings, Inc. has a 52-week low of $78.25 and a 52-week high of $206.85.

Celsius (NASDAQ:CELH) last announced its earnings results on Tuesday, August 8th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.26. Celsius had a negative net margin of 11.60% and a positive return on equity of 66.52%. The company had revenue of $325.88 million during the quarter, compared to analyst estimates of $277.19 million. During the same quarter last year, the firm posted $0.12 earnings per share. Celsius’s revenue was up 111.6% compared to the same quarter last year. As a group, equities analysts predict that Celsius Holdings, Inc. will post 1.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CELH. Maxim Group lowered shares of Celsius from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. B. Riley boosted their price target on Celsius from $190.00 to $230.00 and gave the stock a “buy” rating in a research report on Tuesday. UBS Group raised their price objective on Celsius from $130.00 to $160.00 in a report on Friday, June 2nd. Stephens lifted their target price on shares of Celsius from $180.00 to $200.00 in a research note on Wednesday, August 9th. Finally, Piper Sandler increased their price objective on shares of Celsius from $185.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday, August 29th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Celsius has a consensus rating of “Moderate Buy” and an average target price of $173.80.

Celsius Profile

Celsius Holdings, Inc develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name.